Cargando…
Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma
The anti-programmed cell death-1 protein monoclonal antibody, pembrolizumab is an immune checkpoint inhibitor. While it improves the prognoses of patients with advanced non-small-cell lung cancer, it has been reported to induce various kinds of immune-related adverse events, including hepatotoxicity...
Autores principales: | Kurokawa, Kana, Hara, Munechika, Iwakami, Shin-ichiro, Genda, Takuya, Iwakami, Naoko, Miyashita, Yosuke, Fujioka, Masahiro, Sasaki, Shinichi, Takahashi, Kazuhisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911765/ https://www.ncbi.nlm.nih.gov/pubmed/31735738 http://dx.doi.org/10.2169/internalmedicine.2591-18 |
Ejemplares similares
-
Sarcoidosis with marked necrosis in enlarged lymph nodes mimics mycobacterial infection: a case report
por: Miyashita, Yosuke, et al.
Publicado: (2021) -
EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib
por: Matsuda, Hironari, et al.
Publicado: (2021) -
Hydrocarbon pneumonitis caused by the inhalation of wood preservative
por: Hara, Munechika, et al.
Publicado: (2018) -
Mediastinal pancreatic pseudocyst diagnosed based on black pleural effusion
por: Katayama, Isana, et al.
Publicado: (2023) -
Carcinomatous pleuritis and pericarditis accompanied by pulmonary tuberculosis
por: Hara, Munechika, et al.
Publicado: (2016)